Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04585477

Title field or adapter rule

{'original_value': 'Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:28.072578+00:00

Published At

2026-10-30T00:00:00+00:00

Record Updated At

2026-10-30

Source Retrieved At

2026-10-31T22:18:03.495925+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Non-small Cell Lung Cancer", "Non-small Cell Lung Cancer Stage I", "Non-small Cell Lung Cancer Stage II", "Non-small Cell Lung Cancer Stage III"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-30", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT04585477"

protocolSection.identificationModule.officialTitle

"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Non-small Cell Lung Cancer Stage I (protocolSection.conditionsModule.conditions)
• Non-small Cell Lung Cancer Stage II (protocolSection.conditionsModule.conditions)
• Non-small Cell Lung Cancer Stage III (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Cohort 1 minimal residue disease positive(MRD+)', 'Cohort 2 minimal residue disease negative (MRD-)'], 'description': 'Roche Sequencing and Life Science kit to detect minimal residue disease (MRD)', 'name': 'AVENIO ctDNA Surveillance Kit', 'type': 'DEVICE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort 1 minimal residue disease positive(MRD+)'], 'description': 'Participants in the intervention arm will receive Durvalumab (1500 mg IV every 4 weeks for up to 12 months) as monotherapy or 20mg/kg if weight is 30kg or less.', 'name': 'Durvalumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Cohort 1 minimal residue disease positive(MRD+)', 'Cohort 2 minimal residue disease negative (MRD-)'], 'description': "Participants in the intervention arm (Cohort 1 MRD+) will receive a fixed dose of Durvalumab (1500 mg IV every 4 weeks for up to 12 months), either as monotherapy or in combination with a platinum-based chemotherapy regimen (investigator's choice). Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.", 'name': 'Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Durvalumab (protocolSection.armsInterventionsModule.interventions[].name)
• Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.